Description: Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Home Page: www.merus.nl
Uppsalalaan 17
Utrecht,
3584 CT
Netherlands
Phone:
31 30 253 8800
Officers
| Name | Title |
|---|---|
| Dr. Sven Ante Lundberg M.D. | CEO, President & Executive Director |
| Mr. Gregory D. Perry | Chief Financial Officer |
| Mr. Peter B. Silverman J.D. | EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor |
| Harry Shuman | Chief Accounting Officer |
| Mr. Cornelis Adriaan de Kruif Ph.D. | CTO & Executive VP |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Senior VP |
| Ms. Kathleen Farren | IR & Corporate Communications Officer |
| Ms. Audrey Bergan | Chief People Officer |
| Ms. Shannon Campbell | Executive VP & Chief Commercial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.1838 |
| Price-to-Sales TTM: | 79.4988 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 172 |